Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00169195
Status:
COMPLETED
Last Update Posted:
2015-09-02
First Post:
2005-09-12
Brief Title:
Rituximab Gemcitabine and Oxaliplatin R-GEMOX for RefractoryRelapsed B-cell Lymphoma
Sponsor:
Lymphoma Study Association
Organization:
Lymphoma Study Association
Organization Data
Organization:
Lymphoma Study Association
Class:
OTHER
Study ID:
R-GEMOX
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lymphoma Study Association
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Eli Lilly and Company | INDUSTRY |
| Hoffmann-La Roche | INDUSTRY |
| Sanofi-Synthelabo | INDUSTRY |